Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 5.334
Filtrer
1.
Physiol Res ; 73(3): 381-391, 2024 07 17.
Article de Anglais | MEDLINE | ID: mdl-39027955

RÉSUMÉ

Linoleic acid (LA) not only functions as an essential nutrient, but also profoundly modulates oxidative stress and inflammatory response. However, the potential mechanisms have not been adequately researched. Hence, this study examined the potential pharmacological roles of LA and the underlying mechanisms in mice with lipopolysaccharide (LPS)-associated acute liver injury (ALI). The results indicated that treatment with LA alleviated the histopathological abnormalities in the hepatic and plasma levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and glutathione-S-transferase (GST) in mice with LPS exposure. In addition, LA inhibited the LPS-associated generation of proinflammatory factors, such as tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6), and downregulated the hepatic myeloperoxidase (MPO) level. In addition, the administration of LA resulted in a reduction in hepatic malondialdehyde (MDA) levels and an elevation in liver superoxide dismutase (SOD), reduced glutathione (GSH), catalase (CAT), and glutathione peroxidase (GSH-PX) levels. Further investigations revealed that LA promoted the expression of nuclear factor E2-related factor (Nrf2) and NAD(P)H: quinone oxidoreductase 1 (NQO1). In addition, the beneficial outcomes of LA on LPS-induced acute liver failure were revered when Nrf2 was pharmacologically suppressed by ML385. These experimental results demonstrated that LA supplementation attenuated LPS-associated acute hepatic impairment in mice via the activation of Nrf2.


Sujet(s)
Lésions hépatiques dues aux substances , Acide linoléique , Lipopolysaccharides , Facteur-2 apparenté à NF-E2 , Animaux , Lipopolysaccharides/toxicité , Facteur-2 apparenté à NF-E2/métabolisme , Mâle , Souris , Acide linoléique/pharmacologie , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/traitement médicamenteux , Lésions hépatiques dues aux substances/anatomopathologie , Lésions hépatiques dues aux substances/prévention et contrôle , Stress oxydatif/effets des médicaments et des substances chimiques , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/anatomopathologie
2.
Methods Mol Biol ; 2823: 225-239, 2024.
Article de Anglais | MEDLINE | ID: mdl-39052223

RÉSUMÉ

Quantitative proteomics approaches based on stable isotopic labeling and mass spectrometry have been widely applied to disease research, drug target discovery, biomarker identification, and systems biology. One of the notable stable isotopic labeling approaches is trypsin-catalyzed 18O/16O labeling, which has its own advantages of low sample consumption, simple labeling procedure, cost-effectiveness, and absence of chemical reactions that potentially generate by-products. In this chapter, a protocol for 18O/16O labeling-based quantitative proteomics approach is described with an application to the identification of proteomic biomarkers of acetaminophen (APAP)-induced hepatotoxicity in rats. The protocol involves first the extraction of proteins from liver tissues of control and APAP-treated rats and digestion into peptides by trypsin. After cleaning of the peptides by solid-phase extraction, equal amounts of peptides from the APAP treatment and the control groups are then subject to trypsin-catalyzed 18O/16O labeling. The labeled peptides are combined and fractionated by off-line strong cation exchange liquid chromatography (SCXLC), and each fraction is then analyzed by nanoflow reversed-phase LC coupled online with tandem mass spectrometry (RPLC-MS/MS) for identification and quantification of differential protein expression between APAP-treated rats and controls. The protocol is applicable to quantitative proteomic analysis for a variety of biological samples.


Sujet(s)
Acétaminophène , Marqueurs biologiques , Lésions hépatiques dues aux substances , Marquage isotopique , Foie , Protéomique , Spectrométrie de masse en tandem , Acétaminophène/toxicité , Acétaminophène/effets indésirables , Marquage isotopique/méthodes , Protéomique/méthodes , Animaux , Rats , Marqueurs biologiques/métabolisme , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/anatomopathologie , Lésions hépatiques dues aux substances/étiologie , Spectrométrie de masse en tandem/méthodes , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Protéome/métabolisme , Protéome/analyse , Trypsine/métabolisme , Isotopes de l'oxygène/métabolisme
3.
Cell Biol Toxicol ; 40(1): 59, 2024 Jul 27.
Article de Anglais | MEDLINE | ID: mdl-39060559

RÉSUMÉ

Acute liver injury (ALI) is a common life-threatening condition with a high mortality rate due to liver disease-related death. However, current therapeutic interventions for ALI remain ineffective, and the development of effective novel therapies is urgently needed. Liver samples from patients with drug-induced ALI were collected to detect adenosine kinase (ADK) expression. Male C57BL/6 J mice, hepatocyte-specific ADK knockout (ADKHKO) mice, and their controls (ADKf/f) were exposed to acetaminophen (APAP) and other treatments to investigate the mechanisms of APAP-related ALI. ADK expression was significantly decreased in APAP-injured livers. Hepatocyte-specific ADK deficiency exacerbated APAP-induced ALI, while a gain-of-function approach delivering AAV-ADK, markedly alleviated APAP-induced ALI, as indicated by changes in alanine aminotransferases (ALT) levels, aspartate aminotransferase (AST) levels, neutrophil infiltration and hepatocyte death. This study showed that ADK played a critical role in ALI by activating autophagy through two signaling pathways, the adenosine monophosphate-activated protein kinase (AMPK)-mTOR pathway and the adenosine receptor A1 (ADORA1)-Akt-mTOR pathway. Furthermore, we found that metformin upregulated ADK expression in hepatocytes and protected against APAP-induced ALI. These results demonstrate that ADK is critical in protecting against APAP-induced ALI and that developing therapeutics targeting ADK-adenosine-ADORA1 is a new approach for ALI treatment. Metformin is a potential candidate for preventing ALI by upregulating ADK.


Sujet(s)
Acétaminophène , Adenosine kinase , Autophagie , Lésions hépatiques dues aux substances , Hépatocytes , Souris de lignée C57BL , Souris knockout , Transduction du signal , Acétaminophène/toxicité , Acétaminophène/effets indésirables , Animaux , Hépatocytes/métabolisme , Hépatocytes/effets des médicaments et des substances chimiques , Autophagie/effets des médicaments et des substances chimiques , Mâle , Lésions hépatiques dues aux substances/métabolisme , Souris , Adenosine kinase/métabolisme , Adenosine kinase/génétique , Humains , Transduction du signal/effets des médicaments et des substances chimiques , Sérine-thréonine kinases TOR/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/anatomopathologie , AMP-Activated Protein Kinases/métabolisme
4.
Arch Biochem Biophys ; 758: 110084, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-38971420

RÉSUMÉ

Nuclear factor erythroid factor 2 (Nrf2) is the key regulatory of the antioxidant response elements. Also, Nrf2 interacts with nuclear factor kappa B (NF-ĸB) to inhibit subsequent inflammatory cascade. Activation of Nrf2 signaling ameliorates drug-induced liver injury. Sodium valproate (SVP) is an anti-epilepsy drug with a hepatotoxic adverse effect that restricts its clinical use. In this study, coadministration of Dihydromyricetin (DHM), a natural flavonoid, with SVP to rats upregulated gene expression of Nrf2 and its downstream gene, heme oxygenase 1 (HO-1), while suppressed the Nrf2 repressor, Keap-1. Additionally, DHM led to downregulation of proinflammatory factors in liver tissues, including NF-ĸB, interleukin 1 beta (IL-1ß), and tumor necrosis factor alpha (TNF-α). This was accompanied by a decrease in the proapoptotic protein (cleaved caspase-3) expression level. Furthermore, biochemical and histopathological studies showed that DHM treatment improved liver function and lipid profile while decreased inflammatory cell infiltration, congestion, and hepatocellular damage. According to our knowledge, prior research has not examined the protective effect of DHM on the liver injury induced by SVP. Consequently, this study provides DHM as a promising herbal medication that, when used with SVP, can prevent its induced hepatotoxicity owing to its potential anti-oxidative, anti-inflammatory, and anti-apoptotic properties.


Sujet(s)
Caspase-3 , Lésions hépatiques dues aux substances , Flavonols , Protéine-1 de type kelch associée à ECH , Facteur-2 apparenté à NF-E2 , Facteur de transcription NF-kappa B , Transduction du signal , Acide valproïque , Animaux , Facteur-2 apparenté à NF-E2/métabolisme , Mâle , Transduction du signal/effets des médicaments et des substances chimiques , Flavonols/pharmacologie , Facteur de transcription NF-kappa B/métabolisme , Acide valproïque/pharmacologie , Rats , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/traitement médicamenteux , Lésions hépatiques dues aux substances/prévention et contrôle , Lésions hépatiques dues aux substances/anatomopathologie , Protéine-1 de type kelch associée à ECH/métabolisme , Caspase-3/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/anatomopathologie , Rat Sprague-Dawley , Heme oxygenase (decyclizing)/métabolisme , Heme oxygenase-1/métabolisme
5.
Int J Mol Sci ; 25(13)2024 Jun 22.
Article de Anglais | MEDLINE | ID: mdl-38999973

RÉSUMÉ

Several hepatic disorders are influenced by gut microbiota, but its role in idiosyncratic drug-induced liver injury (iDILI), whose main causative agent is amoxicillin-clavulanate, remains unknown. This pioneering study aims to unravel particular patterns of gut microbiota composition and associated metabolites in iDILI and iDILI patients by amoxicillin-clavulanate (iDILI-AC). Thus, serum and fecal samples from 46 patients were divided into three study groups: healthy controls (n = 10), non-iDILI acute hepatitis (n = 12) and iDILI patients (n = 24). To evaluate the amoxicillin-clavulanate effect, iDILI patients were separated into two subgroups: iDILI non-caused by amoxicillin-clavulanate (iDILI-nonAC) (n = 18) and iDILI-AC patients (n = 6). Gut microbiota composition and fecal metabolome plus serum and fecal bile acid (BA) analyses were performed, along with correlation analyses. iDILI patients presented a particular microbiome profile associated with reduced fecal secondary BAs and fecal metabolites linked to lower inflammation, such as dodecanedioic acid and pyridoxamine. Moreover, certain taxa like Barnesiella, Clostridia UCG-014 and Eubacterium spp. correlated with significant metabolites and BAs. Additionally, comparisons between iDILI-nonAC and iDILI-AC groups unraveled unique features associated with iDILI when caused by amoxicillin-clavulanate. In conclusion, specific gut microbiota profiles in iDILI and iDILI-AC patients were associated with particular metabolic and BA status, which could affect disease onset and progression.


Sujet(s)
Association amoxicilline-clavulanate de potassium , Acides et sels biliaires , Lésions hépatiques dues aux substances , Fèces , Microbiome gastro-intestinal , Métabolome , Humains , Microbiome gastro-intestinal/effets des médicaments et des substances chimiques , Fèces/microbiologie , Acides et sels biliaires/métabolisme , Association amoxicilline-clavulanate de potassium/effets indésirables , Mâle , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/étiologie , Femelle , Métabolome/effets des médicaments et des substances chimiques , Adulte d'âge moyen , Adulte , Sujet âgé
6.
Cell Mol Life Sci ; 81(1): 299, 2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39001944

RÉSUMÉ

BACKGROUND: Acetaminophen (APAP) overdose is a significant contributor to drug-induced liver injury worldwide. G-protein-coupled receptor 116 (GPR116) is an important homeostatic maintenance molecule in the body, but little is known about its role in APAP-induced liver injury (AILI). METHODS: GPR116 expression was determined in both human and mouse AILI models. Hepatic function and damage response were analyzed in hepatocyte-specific GPR116 deletion (GPR116△HC) mice undergoing APAP challenge. RNA-sequencing, immunofluorescence confocal, and co-immunoprecipitation (CO-IP) were employed to elucidate the impact and underlying mechanisms of GPR116 in AILI. RESULTS: Intrahepatic GPR116 was upregulated in human and mice with AILI. GPR116△HC mice were vulnerable to AILI compared to wild-type mice. Overexpression of GPR116 effectively mitigated AILI in wild-type mice and counteracted the heightened susceptibility of GPR116△HC mice to APAP. Mechanistically, GPR116 inhibits the binding immunoglobulin protein (BiP), a critical regulator of ER function, through its interaction with ß-arrestin1, thereby mitigating ER stress during the early stage of AILI. Additionally, the activation of GPR116 by ligand FNDC4 has been shown to confer a protective effect against early hepatotoxicity caused by APAP in murine model. CONCLUSIONS: Upregulation of GPR116 on hepatocytes inhibits ER stress by binding to ß-arrestin1, protecting mice from APAP-induced hepatotoxicity. GPR116 may serve as a promising therapeutic target for AILI.


Sujet(s)
Acétaminophène , Lésions hépatiques dues aux substances , Stress du réticulum endoplasmique , Récepteurs couplés aux protéines G , Animaux , Humains , Mâle , Souris , Acétaminophène/effets indésirables , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/anatomopathologie , Lésions hépatiques dues aux substances/génétique , Modèles animaux de maladie humaine , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Hépatocytes/métabolisme , Hépatocytes/effets des médicaments et des substances chimiques , Hépatocytes/anatomopathologie , Foie/métabolisme , Foie/anatomopathologie , Foie/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Récepteurs couplés aux protéines G/métabolisme , Récepteurs couplés aux protéines G/génétique
7.
Mol Biol Rep ; 51(1): 798, 2024 Jul 13.
Article de Anglais | MEDLINE | ID: mdl-39002019

RÉSUMÉ

BACKGROUND: Hexavalent chromium (CrVI) is known to be a potentially hepatotoxic and nephrotoxic contaminant in humans and other animals, whose toxicity is associated with oxidative stress and inflammation. The aim of this study was to evaluate the potential protective effect of chlorogenic acid (CGA), which has known anti-inflammatory and antioxidant effects, on potassium dichromate (PDC)-induced acute hepatotoxicity and nephrotoxicity in rats. METHODS AND RESULTS: Thirty-six Wistar albino rats were treated with CGA (10, 20, or 40 mg/kg, intraperitoneally) and/or PDC (15 mg/kg/day, intraperitoneally) as a single dose. Serum, liver, and kidney tissues were examined biochemically, histopathologically, and immunohistochemically. Compared to the control group, a significant increase in interleukin-6 (IL-6) levels and a significant decrease in serum and renal reduced glutathione (GSH) levels, liver catalase (CAT), tumour necrosis factor-alpha (TNF-α), and interleukin 1ß (IL-1ß) levels were observed in the PDC group. The administration of PDC led to histopathological and immunohistochemical changes in rat liver and kidney tissues. With the administration of CGA, especially at the 10 mg/kg dosage, the above-mentioned parameters approached normal levels. CONCLUSIONS: CGA had antioxidant and anti-inflammatory effects that alleviated PDC-induced acute hepato- and nephrotoxicity.


Sujet(s)
Antioxydants , Acide chlorogénique , Rein , Foie , Facteur de transcription NF-kappa B , Stress oxydatif , Dichromate de potassium , Rat Wistar , Transduction du signal , Animaux , Dichromate de potassium/toxicité , Acide chlorogénique/pharmacologie , Rats , Transduction du signal/effets des médicaments et des substances chimiques , Facteur de transcription NF-kappa B/métabolisme , Rein/effets des médicaments et des substances chimiques , Rein/métabolisme , Rein/anatomopathologie , Stress oxydatif/effets des médicaments et des substances chimiques , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/anatomopathologie , Mâle , Antioxydants/pharmacologie , Antioxydants/métabolisme , Interleukine-6/métabolisme , Glutathion/métabolisme , Facteur de nécrose tumorale alpha/métabolisme , Interleukine-1 bêta/métabolisme , Catalase/métabolisme , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/traitement médicamenteux
8.
Biosens Bioelectron ; 262: 116573, 2024 Oct 15.
Article de Anglais | MEDLINE | ID: mdl-39018976

RÉSUMÉ

Drug-induced liver injury (DILI) poses a severe threat to public health. Endoplasmic reticulum (ER) stress contributes significantly to DILI pathogenesis, with peroxynitrite (ONOO-) identified as a pivotal indicator. However, the temporal and spatial fluctuations of ONOO- associated with ER stress in the pathogenesis of DILI remain unclear. Herein, a novel ER-specific near-infrared (NIR) probe (QM-ONOO) with aggregation-induced emission (AIE) features for monitoring ONOO- fluctuations in DILI was elaborately constructed. QM-ONOO exhibited excellent ER-targeting specificity, a large Stoke's shift, and a low detection limit (26.9 nM) toward ONOO-. QM-ONOO performed well in imaging both exogenous and endogenous ONOO- in HepG2 cells. Furthermore, molecular docking calculations validated the ER-targeting mechanism of QM-ONOO. Most importantly, using this probe allowed us to intuitively observe the dynamic fluctuations of ONOO- during the formation and remediation processes of DILI in the acetaminophen (APAP)-induced mouse model. Consequently, this work provides a promising tool for in-depth research of ONOO- associated pathological processes in DILI.


Sujet(s)
Acétaminophène , Lésions hépatiques dues aux substances , Réticulum endoplasmique , Colorants fluorescents , Acide peroxynitreux , Acide peroxynitreux/métabolisme , Acide peroxynitreux/composition chimique , Humains , Animaux , Lésions hépatiques dues aux substances/anatomopathologie , Lésions hépatiques dues aux substances/métabolisme , Colorants fluorescents/composition chimique , Réticulum endoplasmique/métabolisme , Souris , Cellules HepG2 , Acétaminophène/toxicité , Acétaminophène/effets indésirables , Techniques de biocapteur/méthodes , Stress du réticulum endoplasmique/effets des médicaments et des substances chimiques , Simulation de docking moléculaire , Imagerie optique/méthodes
9.
Mol Biol Rep ; 51(1): 833, 2024 Jul 22.
Article de Anglais | MEDLINE | ID: mdl-39039363

RÉSUMÉ

BACKGROUND: Hepatotoxicity associated with methotrexate (MTX) is mainly due to disruption of redox balance and development of oxidative injury to hepatocytes. Melatonin (MLT) is a potent antioxidant and regulates wide range of biological functions, processes and utilized as adjuvant for number of medical applications. The current study investigated the mitigating effect of MLT on the MTX-induced hepatotoxicity. METHODS AND RESULTS: Adult male rats received MLT (25 mg/kg, orally) for seven days flowed by single injection of MTX (20 mg/kg, ip) then treat with MLT continued for additional 7 days. The present result showed MLT treatment mitigated histopathological changes in the liver that associated with normalization of ALT and AST activity as well as bilirubin, albumin and alfa-fetoprotein levels in serum of MLT + MTX-treated rat to comparable control level. MLT treatment significantly reduced MDA content and myeloperoxidase activity while enhanced the activity of superoxide dismutase, catalase and glutathione content in the liver indicating the empowerment of the antioxidant status. Amelioration of MLT-induced oxidative stress resulted in a reduction in the inflammatory response due to antioxidant restoration and inhibited apoptosis indicated by downregulation of caspase-3 expression. The replenishment of antioxidant content powers the defense system of the hepatocytes. As a result, apoptosis is reduced which might be due to the ability of MLT protect DNA integrity thus maintaining hepatocyte functions and structure. Consequently, liver histology was protected. CONCLUSIONS: In summary, MLT modulates liver function and structure by orchestrating linked processes, including redox balance, inflammatory response, suppression of caspase-3, and DNA damage.


Sujet(s)
Antioxydants , Apoptose , Lésions hépatiques dues aux substances , Hépatocytes , Foie , Mélatonine , Méthotrexate , Stress oxydatif , Animaux , Méthotrexate/effets indésirables , Méthotrexate/toxicité , Mélatonine/pharmacologie , Rats , Mâle , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/traitement médicamenteux , Stress oxydatif/effets des médicaments et des substances chimiques , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/anatomopathologie , Antioxydants/pharmacologie , Antioxydants/métabolisme , Apoptose/effets des médicaments et des substances chimiques , Hépatocytes/effets des médicaments et des substances chimiques , Hépatocytes/métabolisme , Superoxide dismutase/métabolisme , Glutathion/métabolisme , Catalase/métabolisme
10.
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue ; 36(6): 604-608, 2024 Jun.
Article de Chinois | MEDLINE | ID: mdl-38991959

RÉSUMÉ

OBJECTIVE: To investigate the protective effect of quercetin (QR) on acute liver injury induced by diquat (DQ) poisoning in mice and its mechanism. METHODS: Eighty healthy male C57BL/6 mice with SPF grade were randomly divided into control group, DQ model group, QR treatment group, and QR control group, with 20 mice in each group. The DQ poisoning model was established by a one-time intraperitoneal injection of DQ solution (40 mg/kg); the control and QR control groups received equivalent amounts of distilled water through intraperitoneal injection. Four hours after modeling, the QR treatment group and the QR control group received 0.5 mL QR solution (50 mg/kg) through gavage. Meanwhile, an equivalent amount of distilled water was given orally to the control group and the DQ model group. The treatments above were administered once daily for seven consecutive days. Afterwards, the mice were anesthetized, blood and liver tissues were collected for following tests: changes in the structure of mice liver tissue were observed using transmission electron microscopy; the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were detected using enzyme linked immunosorbent assay (ELISA); the levels of glutathione (GSH), superoxide dismutase (SOD), and malondialdehyde (MDA) in liver tissues were measured using the water-soluble tetrazolium-1 (WST-1) method, the thiobarbituric acid (TBA) method, and enzymatic methods, respectively; the protein expressions of nuclear factor erythroid 2-related factor 2 (Nrf2), heme oxygenase-1 (HO-1), Kelch-like ECH-associated protein 1 (Keap1), and activated caspase-9 in liver tissues were detected using Western blotting. RESULTS: Severe mitochondrial damage was observed in the liver tissues of mice in the DQ model group using transmission electron microscopy, yet mitochondrial damage in the QR treatment group showed significant alleviation. Compared to the control group, the DQ model group had significantly increased levels of MDA in liver tissue, serum AST, and ALT, yet had significantly decreased levels of GSH and SOD in liver tissue. In comparison to the DQ model group, the QR treatment group exhibited significant reductions in serum levels of ALT and AST, as well as MDA levels in liver tissue [ALT (U/L): 52.60±6.44 vs. 95.70±8.00, AST (U/L): 170.45±19.33 vs. 251.10±13.09, MDA (nmol/mg): 12.63±3.41 vs. 18.04±3.72], and notable increases in GSH and SOD levels in liver tissue [GSH (µmol/mg): 39.49±6.33 vs. 20.26±3.96, SOD (U/mg): 121.40±11.75 vs. 81.67±10.01], all the differences were statistically significant (all P < 0.01). Western blotting results indicated that the protein expressions of Nrf2 and HO-1 in liver tissues of the DQ model group were significantly decreased compared to the control group. On the other hand, the protein expressions of Keap1 and activated caspase-9 were conspicuously higher when compared to the control group. In comparison to the DQ model group, the QR treatment group showed a significant increase in the protein expressions of Nrf2 and HO-1 in liver tissues (Nrf2/ß-actin: 1.17±0.08 vs. 0.92±0.45, HO-1/ß-actin: 1.53±0.17 vs. 0.84±0.09). By contrast, there was a notable decrease in the protein expressions of Keap1 and activated caspase-9 (Keap1/ß-actin: 0.48±0.06 vs. 1.22±0.09, activated caspase-9/ß-actin: 1.17±0.12 vs. 1.59±0.30), the differences were statistically significant (all P < 0.01). CONCLUSIONS: QR may reduce acute liver injury induced by DQ poisoning in mice via activating Keap1/Nrf2 signaling pathway.


Sujet(s)
Lésions hépatiques dues aux substances , Diquat , Foie , Souris de lignée C57BL , Quercétine , Animaux , Mâle , Souris , Quercétine/pharmacologie , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/traitement médicamenteux , Caspase-9/métabolisme , Protéine-1 de type kelch associée à ECH/métabolisme , Stress oxydatif/effets des médicaments et des substances chimiques , Facteur-2 apparenté à NF-E2/métabolisme , Alanine transaminase/sang , Protéines membranaires , Heme oxygenase-1
11.
Cell Rep Med ; 5(7): 101653, 2024 Jul 16.
Article de Anglais | MEDLINE | ID: mdl-39019009

RÉSUMÉ

Drug-induced liver injury (DILI) is a significant cause of acute liver failure (ALF) and liver transplantation in the Western world. Acetaminophen (APAP) overdose is a main contributor of DILI, leading to hepatocyte cell death through necrosis. Here, we identified that neddylation, an essential post-translational modification involved in the mitochondria function, was upregulated in liver biopsies from patients with APAP-induced liver injury (AILI) and in mice treated with an APAP overdose. MLN4924, an inhibitor of the neuronal precursor cell-expressed developmentally downregulated protein 8 (NEDD8)-activating enzyme (NAE-1), ameliorated necrosis and boosted liver regeneration in AILI. To understand how neddylation interferes in AILI, whole-body biotinylated NEDD8 (bioNEDD8) and ubiquitin (bioUB) transgenic mice were investigated under APAP overdose with and without MLN4924. The cytidine diphosphate diacylglycerol (CDP-DAG) synthase TAM41, responsible for producing cardiolipin essential for mitochondrial activity, was found modulated under AILI and restored its levels by inhibiting neddylation. Understanding this ubiquitin-like crosstalk in AILI is essential for developing promising targeted inhibitors for DILI treatment.


Sujet(s)
Acétaminophène , Cardiolipides , Lésions hépatiques dues aux substances , Cyclopentanes , Protéine NEDD8 , Pyrimidines , Acétaminophène/effets indésirables , Animaux , Protéine NEDD8/métabolisme , Protéine NEDD8/génétique , Humains , Pyrimidines/pharmacologie , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/anatomopathologie , Lésions hépatiques dues aux substances/traitement médicamenteux , Cardiolipides/métabolisme , Souris , Cyclopentanes/pharmacologie , Mâle , Foie/métabolisme , Foie/anatomopathologie , Foie/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Souris transgéniques , Hépatocytes/métabolisme , Hépatocytes/effets des médicaments et des substances chimiques , Hépatocytes/anatomopathologie , Transduction du signal/effets des médicaments et des substances chimiques , Ubiquitin-activating enzymes/métabolisme , Ubiquitin-activating enzymes/génétique , Ubiquitin-activating enzymes/antagonistes et inhibiteurs
12.
Zhen Ci Yan Jiu ; 49(7): 686-692, 2024 Jul 25.
Article de Anglais, Chinois | MEDLINE | ID: mdl-39020486

RÉSUMÉ

OBJECTIVES: To investigate the mechanism of the effect of acupuncture and moxibustion on improving liver injury in cisplatin (DDP) induced liver injury model mice by observing the changes of inositol-requiring enzyme (IRE) -1 signaling pathway. METHODS: Forty KM mice were randomly divided into control, model, acupuncture and moxibustion groups, with 10 mice in each group. The liver injury model was replicated by intraperitoneal injection of DDP (10 mg/kg). In the acupuncture group and the moxibustion group, acupuncture and moxibustion were performed at "Dazhui"(GV14), and bilateral "Ganshu"(BL18), "Shenshu" (BL23), and "Zusanli"(ST36), respectively for 6 min, once per day for 7 d. The apoptosis of hepatocytes was detected by TUNEL staining. The expression of phosphorylation(p)-IRE-1α, glucose-regulated protein (Grp) 78 and cysteine aspartic protease (Caspase) -12 in liver tissue were detected by immunohistochemistry and Western blot, respectively. The expression levels of Grp78 and Caspase-12 mRNA in liver tissue were detected by quantitative real-time PCR. RESULTS: Compared with the control group, the apoptosis rate of hepatocytes was increased (P<0.05), the positive expression and protein expression of p-IRE-1α, Grp78, and Caspase-12 were increased (P<0.05), the expression levels of Grp78 and Caspase-12 mRNA were increased (P<0.05) in the model group. Compared with the model group, all these indicators showed opposite trends (P<0.05) in the acupuncture and moxibustion groups. CONCLUSIONS: Acupuncture and moxibustion can reduce liver injury due to DDP chemotherapy by modulating IRE-1 signaling pathway, inhibiting the excessive activation of endoplasmic reticulum stress, and reducing liver cell apoptosis.


Sujet(s)
Thérapie par acupuncture , Apoptose , Cisplatine , Chaperonne BiP du réticulum endoplasmique , Foie , Moxibustion , Protein-Serine-Threonine Kinases , Transduction du signal , Animaux , Souris , Mâle , Humains , Foie/métabolisme , Foie/traumatismes , Protein-Serine-Threonine Kinases/métabolisme , Protein-Serine-Threonine Kinases/génétique , Endoribonucleases/métabolisme , Endoribonucleases/génétique , Lésions hépatiques dues aux substances/thérapie , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/génétique , Points d'acupuncture , Protéines du choc thermique/métabolisme , Protéines du choc thermique/génétique , Caspase-12/métabolisme , Caspase-12/génétique , Hépatocytes/métabolisme
14.
Front Immunol ; 15: 1371446, 2024.
Article de Anglais | MEDLINE | ID: mdl-38994365

RÉSUMÉ

Background: Acetaminophen (APAP) is commonly used as an antipyretic analgesic. However, acetaminophen overdose may contribute to liver injury and even liver failure. Acetaminophen-induced liver injury (AILI) is closely related to mitochondrial oxidative stress and dysfunction, which play critical roles in cuproptosis. Here, we explored the potential role of cuproptosis-related genes (CRGs) in AILI. Methods: The gene expression profiles were obtained from the Gene Expression Omnibus database. The differential expression of CRGs was determined between the AILI and control samples. Protein protein interaction, correlation, and functional enrichment analyses were performed. Machine learning was used to identify hub genes. Immune infiltration was evaluated. The AILI mouse model was established by intraperitoneal injection of APAP solution. Quantitative real-time PCR and western blotting were used to validate hub gene expression in the AILI mouse model. The copper content in the mouse liver samples and AML12 cells were quantified using a colorimetric assay kit. Ammonium tetrathiomolybdate (ATTM), was administered to mouse models and AML12 cells in order to investigate the effects of copper chelator on AILI. Results: The analysis identified 7,809 differentially expressed genes, 4,245 of which were downregulated and 3,564 of which were upregulated. Four optimal feature genes (OFGs; SDHB, PDHA1, NDUFB2, and NDUFB6) were identified through the intersection of two machine learning algorithms. Further nomogram, decision curve, and calibration curve analyses confirmed the diagnostic predictive efficacy of the four OFGs. Enrichment analysis indicated that the OFGs were involved in multiple pathways, such as IL-17 pathway and chemokine signaling pathway, that are related to AILI progression. Immune infiltration analysis revealed that macrophages were more abundant in AILI than in control samples, whereas eosinophils and endothelial cells were less abundant. Subsequently, the AILI mouse model was successfully established, and histopathological analysis using hematoxylin-eosin staining along with liver function tests revealed a significant induction of liver injury in the APAP group. Consistent with expectations, both mRNA and protein levels of the four OFGs exhibited a substantial decrease. The administration of ATTAM effectively mitigates copper elevation induced by APAP in both mouse model and AML12 cells. However, systemic administration of ATTM did not significantly alleviate AILI in the mouse model. Conclusion: This study first revealed the potential role of CRGs in the pathological process of AILI and offered novel insights into its underlying pathogenesis.


Sujet(s)
Acétaminophène , Lésions hépatiques dues aux substances , Biologie informatique , Apprentissage machine , Acétaminophène/effets indésirables , Acétaminophène/toxicité , Animaux , Souris , Biologie informatique/méthodes , Lésions hépatiques dues aux substances/génétique , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/immunologie , Cuivre , Modèles animaux de maladie humaine , Mâle , Souris de lignée C57BL , Analyse de profil d'expression de gènes , Transcriptome , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Cartes d'interactions protéiques
15.
Int J Mol Sci ; 25(13)2024 Jun 30.
Article de Anglais | MEDLINE | ID: mdl-39000343

RÉSUMÉ

Mesenchymal stem cells (MSCs) have shown great potential for the treatment of liver injuries, and the therapeutic efficacy greatly depends on their homing to the site of injury. In the present study, we detected significant upregulation of hepatocyte growth factor (HGF) in the serum and liver in mice with acute or chronic liver injury. In vitro study revealed that upregulation of miR-9-5p or miR-221-3p promoted the migration of human MSCs (hMSCs) toward HGF. Moreover, overexpression of miR-9-5p or miR-221-3p promoted hMSC homing to the injured liver and resulted in significantly higher engraftment upon peripheral infusion. hMSCs reduced hepatic necrosis and inflammatory infiltration but showed little effect on extracellular matrix (ECM) deposition. By contrast, hMSCs overexpressing miR-9-5p or miR-221-3p resulted in not only less centrilobular necrosis and venous congestion but also a significant reduction of ECM deposition, leading to obvious improvement of hepatocyte morphology and alleviation of fibrosis around central vein and portal triads. Further studies showed that hMSCs inhibited the activation of hepatic stellate cells (HSCs) but could not decrease the expression of TIMP-1 upon acute injury and the expression of MCP-1 and TIMP-1 upon chronic injury, while hMSCs overexpressing miR-9-5p or miR-221-3p led to further inactivation of HSCs and downregulation of all three fibrogenic and proinflammatory factors TGF-ß, MCP-1, and TIMP-1 upon both acute and chronic injuries. Overexpression of miR-9-5p or miR-221-3p significantly downregulated the expression of α-SMA and Col-1α1 in activated human hepatic stellate cell line LX-2, suggesting that miR-9-5p and miR-221-3p may partially contribute to the alleviation of liver injury by preventing HSC activation and collagen expression, shedding light on improving the therapeutic efficacy of hMSCs via microRNA modification.


Sujet(s)
Cellules étoilées du foie , Transplantation de cellules souches mésenchymateuses , Cellules souches mésenchymateuses , microARN , microARN/génétique , microARN/métabolisme , Humains , Cellules souches mésenchymateuses/métabolisme , Cellules étoilées du foie/métabolisme , Animaux , Souris , Transplantation de cellules souches mésenchymateuses/méthodes , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/thérapie , Lésions hépatiques dues aux substances/génétique , Mâle , Tétrachloro-méthane/effets indésirables , Facteur de croissance des hépatocytes/métabolisme , Facteur de croissance des hépatocytes/génétique , Souris de lignée C57BL , Mouvement cellulaire
16.
Biomed Pharmacother ; 177: 117163, 2024 Aug.
Article de Anglais | MEDLINE | ID: mdl-39018876

RÉSUMÉ

Graveoline exhibits various biological activities. However, only limited studies have focused on its hepatoprotective properties. This study evaluated the anti-inflammatory and hepatoprotective activities of graveoline, a minor 2-phenylquinolin-4-one alkaloid isolated from Ruta graveolens L., in a liver injury model in vitro and in vivo. A network pharmacology approach was used to investigate the potential signaling pathway associated with the hepatoprotective activity of graveoline. Subsequently, biological experiments were conducted to validate the findings. Topological analysis of the KEGG pathway enrichment revealed that graveoline mediates its hepatoprotective activity through genes associated with the hepatitis B viral infection pathway. Biological experiments demonstrated that graveoline effectively reduced the levels of alanine transaminase and aspartate transaminase in lipopolysaccharide (LPS)-induced HepG2 cells. Graveoline exerted antihepatitic activity by inhibiting the pro-inflammatory cytokine tumor necrosis factor-α (TNF-α) and elevated the anti-inflammatory cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) in vitro and in vivo. Additionally, graveoline exerted its hepatoprotective activity by inhibiting JAK1 and STAT3 phosphorylation both in vitro and in vivo. In summary, graveoline can attenuate acute liver injury by inhibiting the TNF-α inflammasome, activating IL-4 and IL-10, and suppressing the JAK1/STAT3 signaling pathway. This study sheds light on the potential of graveoline as a promising therapeutic agent for treating liver injury.


Sujet(s)
Lésions hépatiques dues aux substances , Galactosamine , Janus kinase 1 , Lipopolysaccharides , Facteur de transcription STAT-3 , Transduction du signal , Facteur de transcription STAT-3/métabolisme , Janus kinase 1/métabolisme , Janus kinase 1/antagonistes et inhibiteurs , Animaux , Humains , Lipopolysaccharides/toxicité , Transduction du signal/effets des médicaments et des substances chimiques , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/prévention et contrôle , Lésions hépatiques dues aux substances/traitement médicamenteux , Mâle , Cellules HepG2 , Galactosamine/toxicité , Souris , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/isolement et purification , Cytokines/métabolisme , Quinoléines/pharmacologie
17.
Sci Rep ; 14(1): 16756, 2024 Jul 20.
Article de Anglais | MEDLINE | ID: mdl-39033253

RÉSUMÉ

Emodin (EMO) has the effect of anti-cholestasis induced by alpha-naphthylisothiocyanate (ANIT). But its mechanism is still unclear. The farnesoid X receptor (Fxr) is the master bile acid nuclear receptor. Recent studies have reported that Sirtuin 1 (Sirt1) can regulate the activities of Fxr. The purpose of the current study was to investigate the mechanism of EMO against ANIT-induced liver injury based on Sirt1/Fxr signaling pathway. The ANIT-induced cholestatic rats were used with or without EMO treatment. Serum biochemical indicators, as well as liver histopathological changes were examined. The genes expressions of Sirt1, Fxr, Shp, Bsep and Mrp2 were detected. The expressions of Sirt1, Fxr and their downstream related genes were investigated in vitro. The results showed that EMO significantly alleviated ANIT-induced liver injury in rats, and increased Sirt1, Fxr, Shp, Bsep and Mrp2 gene expression in liver, while decreased the expression of Cyp7a1. EMO significantly activated Fxr, while Sirt1 inhibitor and Sirt1 gene silencing significantly reduced Fxr activity in vitro. Collectively, EMO in the right dose has a protective effect on liver injury induced by ANIT, and the mechanism may be through activation of Fxr by Sirt1, thus regulating bile acid metabolism, and reducing bile acid load in hepatocytes.


Sujet(s)
1-Naphtyl-isothiocyanate , Cholestase , Émodine , Récepteurs cytoplasmiques et nucléaires , Transduction du signal , Sirtuine-1 , Animaux , Sirtuine-1/métabolisme , Sirtuine-1/génétique , Récepteurs cytoplasmiques et nucléaires/métabolisme , Transduction du signal/effets des médicaments et des substances chimiques , Émodine/pharmacologie , Émodine/usage thérapeutique , Cholestase/métabolisme , Cholestase/traitement médicamenteux , Cholestase/anatomopathologie , Rats , Mâle , 1-Naphtyl-isothiocyanate/toxicité , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Foie/traumatismes , Acides et sels biliaires/métabolisme , Humains , Rat Sprague-Dawley , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/traitement médicamenteux , Lésions hépatiques dues aux substances/anatomopathologie , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Cellules HepG2
18.
PeerJ ; 12: e17687, 2024.
Article de Anglais | MEDLINE | ID: mdl-39056050

RÉSUMÉ

Background: Cisplatin (CIS) is a broad-spectrum anticancer drug, with cytotoxic effects on either malignant or normal cells. We aimed to evaluate the hepatotoxicity in rats caused by CIS and its amelioration by the co-administration of either curcumin or resveratrol. Materials and Methods: Forty adult male rats divided into four equal groups: (control group): rats were given a saline solution (0.9%) once intraperitoneally, daily for the next 28 days; (cisplatin group): rats were given a daily oral dose of saline solution (0.9%) for 28 days after receiving a single dose of cisplatin (3.3 mg/kg) intraperitoneally for three successive days; (CIS plus curcumin/resveratrol groups): rats received the same previous dose of cisplatin (3.3 mg/kg) daily for three successive days followed by oral administration of either curcumin/resveratrol solution at a dose of (20 mg/kg) or (10 mg/kg) consequently daily for 28 days. Different laboratory tests (ALT, AST, ALP, bilirubin, oxidative stress markers) and light microscopic investigations were done. Results: Administration of CIS resulted in hepatotoxicity in the form of increased liver enzymes, oxidative stress markers; degenerative and apoptotic changes, the co-administration of CIS with either curcumin or resveratrol improved hepatotoxicity through improved microscopic structural changes, reduction in liver enzymes activity, decreased oxidative stress markers, improved degenerative, and apoptotic changes in liver tissues. Conclusion: Co-administration of either curcumin or resveratrol with cisplatin treatment could ameliorate hepatotoxicity caused by cisplatin in rats via anti-inflammatory and oxidative stress-apoptotic pathways.


Sujet(s)
Apoptose , Lésions hépatiques dues aux substances , Cisplatine , Curcumine , Stress oxydatif , Resvératrol , Animaux , Resvératrol/pharmacologie , Resvératrol/administration et posologie , Cisplatine/toxicité , Cisplatine/administration et posologie , Curcumine/pharmacologie , Curcumine/administration et posologie , Stress oxydatif/effets des médicaments et des substances chimiques , Mâle , Rats , Apoptose/effets des médicaments et des substances chimiques , Lésions hépatiques dues aux substances/anatomopathologie , Lésions hépatiques dues aux substances/traitement médicamenteux , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/prévention et contrôle , Lésions hépatiques dues aux substances/étiologie , Antinéoplasiques/administration et posologie , Antinéoplasiques/effets indésirables , Antinéoplasiques/toxicité , Foie/effets des médicaments et des substances chimiques , Foie/métabolisme , Foie/anatomopathologie , Antioxydants/pharmacologie , Antioxydants/administration et posologie , Stilbènes/administration et posologie , Stilbènes/pharmacologie , Stilbènes/usage thérapeutique , Anti-inflammatoires/pharmacologie , Anti-inflammatoires/administration et posologie , Rat Wistar
19.
Eur J Pharmacol ; 978: 176774, 2024 Sep 05.
Article de Anglais | MEDLINE | ID: mdl-38936452

RÉSUMÉ

AIM: Given estrogen's recognized regulatory influence on diverse metabolic and immune functions, this study sought to explore its potential impact on fibrosis and elucidate the underlying metabolic regulations. METHODS: Female mice underwent ovary removal surgery, followed by carbon tetrachloride (CCl4) administration to induce liver injury. Biochemical index analysis and histopathological examination were then conducted. The expression levels of alpha-smooth muscle actin (α-SMA), transforming growth factor-ß (TGF-ß), and collagen type 1 alpha 1 chain (COL1A1) were assessed using western blotting to further elucidate the extent of liver injury. Finally, metabolite extraction and metabolomic analysis were performed to evaluate metabolic changes. RESULTS: Ovary removal exacerbated CCl4-induced liver damage, while estrogen supplementation provided protection against hepatic changes resulting from OVX. Furthermore, estrogen mitigated liver injury induced by CCl4 treatment in vivo. Estrogen supplementation significantly restored liver damage induced by OVX and CCl4. Comparative analysis revealed significant alterations in pathways including aminoacyl-tRNA biosynthesis, glycine, serine, and threonine metabolism, lysine degradation, and taurine and hypotaurine metabolism in estrogen treatment. CONCLUSION: Estrogen supplementation alleviates liver injury induced by OVX and CCl4, highlighting its protective effects against fibrosis and associated metabolic alterations.


Sujet(s)
Tétrachloro-méthane , Oestrogènes , Homéostasie , Cirrhose du foie , Ovariectomie , Animaux , Femelle , Tétrachloro-méthane/toxicité , Souris , Oestrogènes/pharmacologie , Cirrhose du foie/métabolisme , Cirrhose du foie/anatomopathologie , Cirrhose du foie/traitement médicamenteux , Homéostasie/effets des médicaments et des substances chimiques , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Foie/métabolisme , Lésions hépatiques dues aux substances/métabolisme , Lésions hépatiques dues aux substances/anatomopathologie , Lésions hépatiques dues aux substances/traitement médicamenteux , Lésions hépatiques dues aux substances/prévention et contrôle , Lésions hépatiques dues aux substances/étiologie , Souris de lignée C57BL , Collagène de type I/métabolisme , Facteur de croissance transformant bêta/métabolisme
20.
Theranostics ; 14(8): 3029-3042, 2024.
Article de Anglais | MEDLINE | ID: mdl-38855187

RÉSUMÉ

Acetaminophen (APAP) overdosing is a major cause of acute liver failure worldwide and an established model for drug-induced acute liver injury (ALI). While studying gene expression during murine APAP-induced ALI by 3'mRNA sequencing (massive analysis of cDNA ends, MACE), we observed splenic mRNA accumulation encoding for the neutrophil serine proteases cathepsin G, neutrophil elastase, and proteinase-3 - all are hierarchically activated by cathepsin C (CtsC). This, along with increased serum levels of these proteases in diseased mice, concurs with the established phenomenon of myeloid cell mobilization during APAP intoxication. Objective: In order to functionally characterize CtsC in murine APAP-induced ALI, effects of its genetic or pharmacological inhibition were investigated. Methods and Results: We report on substantially reduced APAP toxicity in CtsC deficient mice. Alleviation of disease was likewise observed by treating mice with the CtsC inhibitor AZD7986, both in short-term prophylactic and therapeutic protocols. This latter observation indicates a mode of action beyond inhibition of granule-associated serine proteases. Protection in CtsC knockout or AZD7986-treated wildtype mice was unrelated to APAP metabolization but, as revealed by MACE, realtime PCR, or ELISA, associated with impaired expression of inflammatory genes with proven pathogenic roles in ALI. Genes consistently downregulated in protocols tested herein included cxcl2, mmp9, and angpt2. Moreover, ptpn22, a positive regulator of the toll-like receptor/interferon-axis, was reduced by targeting CtsC. Conclusions: This work suggests CtsC as promising therapeutic target for the treatment of ALI, among others paradigmatic APAP-induced ALI. Being also currently evaluated in phase III clinical trials for bronchiectasis, successful application of AZD7986 in experimental APAP intoxication emphasizes the translational potential of this latter therapeutic approach.


Sujet(s)
Acétaminophène , Cathepsine C , Lésions hépatiques dues aux substances , Animaux , Mâle , Souris , Acétaminophène/effets indésirables , Cathepsine C/métabolisme , Cathepsine C/génétique , Lésions hépatiques dues aux substances/traitement médicamenteux , Lésions hépatiques dues aux substances/métabolisme , Modèles animaux de maladie humaine , Souris de lignée C57BL , Souris knockout
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE